Nanobiotix (NBTX) Stock Forecast, Price Target & Predictions
NBTX Stock Forecast
Nanobiotix stock forecast is as follows: an average price target of $12.00 (represents a 302.68% upside from NBTX’s last price of $2.98) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
NBTX Price Target
NBTX Analyst Ratings
Buy
Nanobiotix Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Aug 27, 2024 | Michael Schmidt | Guggenheim | $12.00 | $5.13 | 133.92% | 302.68% |
Nanobiotix Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 1 |
Avg Price Target | - | - | $12.00 |
Last Closing Price | $2.98 | $2.98 | $2.98 |
Upside/Downside | -100.00% | -100.00% | 302.68% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 27, 2024 | Guggenheim | Buy | Initialise |
Nanobiotix Financial Forecast
Nanobiotix Revenue Forecast
Quarter
Jun 24 | |
---|---|
Revenue | - |
Avg Forecast | $23.27M |
High Forecast | $23.27M |
Low Forecast | $23.27M |
# Analysts | 1 |
Surprise % | - |
Forecast
Nanobiotix EBITDA Forecast
Quarter
Jun 24 | |
---|---|
# Analysts | 1 |
EBITDA | - |
Avg Forecast | $-23.27M |
High Forecast | $-23.27M |
Low Forecast | $-23.27M |
Surprise % | - |
Forecast
Nanobiotix Net Income Forecast
Quarter
Jun 24 | |
---|---|
# Analysts | 1 |
Net Income | - |
Avg Forecast | $-10.71M |
High Forecast | $-10.71M |
Low Forecast | $-10.71M |
Surprise % | - |
Forecast
Nanobiotix SG&A Forecast
Quarter
Jun 24 | |
---|---|
# Analysts | 1 |
SG&A | - |
Avg Forecast | $11.67B |
High Forecast | $11.67B |
Low Forecast | $11.67B |
Surprise % | - |
Forecast
Nanobiotix EPS Forecast
Quarter
Jun 24 | |
---|---|
# Analysts | 1 |
EPS | - |
Avg Forecast | $-0.23 |
High Forecast | $-0.23 |
Low Forecast | $-0.23 |
Surprise % | - |
Forecast
Nanobiotix Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
HEPA | Hepion Pharmaceuticals | $0.52 | $70.00 | 13361.54% | Buy |
INAB | IN8bio | $0.29 | $14.00 | 4727.59% | Buy |
DRMA | Dermata Therapeutics | $1.10 | $6.00 | 445.45% | Buy |
CNSP | CNS Pharmaceuticals | $0.11 | $0.50 | 354.55% | |
TCRX | TScan Therapeutics | $2.97 | $12.00 | 304.04% | Buy |
ZURA | Zura Bio | $2.51 | $10.00 | 298.41% | Buy |
NBTX | Nanobiotix | $3.54 | $12.00 | 238.98% | Buy |
IMMX | Immix Biopharma | $2.29 | $7.00 | 205.68% | Buy |
ANNX | Annexon | $4.88 | $14.00 | 186.89% | Buy |
CUE | Cue Biopharma | $1.06 | $3.00 | 183.02% | Buy |
WVE | Wave Life Sciences | $14.45 | $22.14 | 53.22% | Buy |
PALI | Palisade Bio | $1.90 | $1.50 | -21.05% | Buy |